Update on strategies to increase HDL quantity and function

被引:155
作者
Duffy, Danielle [2 ]
Rader, Daniel J. [1 ]
机构
[1] Univ Penn, Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA
[2] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
关键词
ESTER TRANSFER PROTEIN; REVERSE CHOLESTEROL TRANSPORT; HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; EXTENDED-RELEASE NIACIN; PPAR-ALPHA AGONIST; NICOTINIC-ACID; ENDOTHELIAL LIPASE; MOLECULAR-IDENTIFICATION; CORONARY ATHEROSCLEROSIS;
D O I
10.1038/nrcardio.2009.94
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Low levels of HDL cholesterol are a significant predictor of atherosclerotic cardiovascular events. HDL is believed to protect against atherosclerosis by promoting reverse cholesterol transport, and potentially through anti-inflammatory, antioxidative, antithrombotic and nitric oxide effects. The multiple mechanisms of action, as well as a limited ability to measure these properties, make HDL a complex therapeutic target, albeit one with immense potential for the treatment of patients with atherosclerosis. Here, we discuss new therapeutic strategies currently being developed, which have the potential to increase plasma levels of HDL cholesterol and/or improve HDL function.
引用
收藏
页码:455 / 463
页数:9
相关论文
共 92 条
[1]   Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides [J].
Anantharamaiah, G. M. ;
Mishra, Vinod K. ;
Garber, David W. ;
Datta, Geeta ;
Handattu, Shaila P. ;
Palgunachari, Mayakonda N. ;
Chaddha, Manjula ;
Navab, Mohamad ;
Reddy, Srinivasa T. ;
Segrest, Jere P. ;
Fogelman, Alan M. .
JOURNAL OF LIPID RESEARCH, 2007, 48 (09) :1915-1923
[2]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[3]   Endothelial lipase is increased in vivo by inflammation in humans [J].
Badellino, Karen O. ;
Wolfe, Megan L. ;
Reilly, Muredach P. ;
Rader, Daniel J. .
CIRCULATION, 2008, 117 (05) :678-685
[4]   Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis [J].
Badellino, KO ;
Wolfe, ML ;
Reilly, MP ;
Rader, DJ .
PLOS MEDICINE, 2006, 3 (02) :245-252
[5]   HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events [J].
Barter, Philip ;
Gotto, Antonio M. ;
LaRosa, John C. ;
Maroni, Jaman ;
Szarek, Michael ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Bittner, Vera ;
Fruchart, Jean-Charles .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (13) :1301-1310
[6]   Effects of torcetrapib in patients at high risk for coronary events [J].
Barter, Philip J. ;
Caulfield, Mark ;
Eriksson, Mats ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Mosca, Lori ;
Tardif, Jean-Claude ;
Waters, David D. ;
Shear, Charles L. ;
Revkin, James H. ;
Buhr, Kevin A. ;
Fisher, Marian R. ;
Tall, Alan R. ;
Brewer, Bryan .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122
[7]   GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing [J].
Benyó, Z ;
Gille, A ;
Kero, J ;
Csiky, M ;
Suchánková, MC ;
Nüsing, RM ;
Moers, A ;
Pfeffer, K ;
Offermanns, S .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (12) :3634-3640
[8]   Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients [J].
Bloedon, LeAnne T. ;
Dunbar, Richard ;
Duffy, Danielle ;
Pinell-Salles, Paula ;
Norris, Robert ;
DeGroot, Bruce J. ;
Movva, Rajesh ;
Navab, Mohamad ;
Fogelman, Alan M. ;
Rader, Daniel J. .
JOURNAL OF LIPID RESEARCH, 2008, 49 (06) :1344-1352
[9]   Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients [J].
Bloomfield, Daniel ;
Carlson, Gary L. ;
Sapre, Aditi ;
Tribble, Diane ;
McKenney, James M. ;
Littlejohn, Thomas W., III ;
Sisk, Christine McCrary ;
Mitchel, Yale ;
Pasternak, Richard C. .
AMERICAN HEART JOURNAL, 2009, 157 (02) :352-U20
[10]  
Boden WE., 2000, The American Journal of Cardiology, V86, P19, DOI DOI 10.1016/S0002-9149(00)01464-8